Xerosis
8
2
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (8)
Dermatological Acceptability and Efficacy in Improving Xerosis, Skin Hydration, and Barrier Function
Novel Skin Barrier Product Versus Petrolatum for Skin Barrier Dysfunction
Clinical Therapeutic Potential of Novel Microbiome LP-51 on Xerosis Individual Based on Xerosis-microbiome Index
Efficacy Study of Cosmetic Product on Xerosis Induced by Systemic Anticancer Treatments
Combined Effect of Acitretin and Narrow Band Ultraviolet B on Vitiligo Repigmentation
The Role of Skin Care Regimen in Skin Health
Skin Barrier Biophysical Properties and Clinical Appearance After Moisturizer in Dry Skin
Safety and Efficacy of SQIN™ on Xerosis in Adults With Mobility Problems and Paralysis